Figure 7.

Combinatorial effects of ¹⁷⁷Lu-anti-CD55 and cisplatin in vitro and in vivo. (a) Cell viability assays of H460 lung cancer cells treated with 0.1 MBq of ¹⁷⁷Lu-anti-CD55 in the presence or absence of 3 μM cisplatin (n = 3; *P < 0.05; Student’s t test). The results are presented as the mean ± SEM (error bars). (b) Cell viability assays of H358 lung cancer cells treated with 0.1 MBq of ¹⁷⁷Lu-anti-CD55 in the presence or absence of 3 μM cisplatin (n = 3; *P < 0.05; Student’s t test). The results are presented as the mean ± SEM (error bars). (c) Effects of ¹⁷⁷Lu-anti-CD55 in the presence or absence of cisplatin on the survival of early pleural metastatic mice (n = 10 for each group; ***P < 0.001; Log-rank (Mantel-Cox) test). (d) Analysis of the survival of pleural metastatic mice after treatment with ¹⁷⁷Lu-anti-CD55 in the presence or absence of cisplatin (n = 10 for each group).